Adjuvant low-dose interferon α2a with or without dacarbazine compared with surgery alone: A prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis

Annals of Oncology

Volumn 19, Issue 6, 2008, Pages 1195-1201

  Garbe, Claus ^a   Radny, P ^a   Linse, R ^b   Dummer, R ^c   Gutzmer, R ^d   Ulrich, J ^e   Stadler, R ^b   Weichenthal, M ^g   Eigentler, T K ^a   Ellwanger, U ^f   Hauschild, A ^g  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Department of Dermatology ^*  (Germany)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e OTTO VON GUERICKE UNIVERSITY   (Germany)

^f DatInf GmbH   (Germany)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Adjuvant treatment; Dacarbazine; Immunotherapy, interferon ; Melanoma

Indexed keywords

ALPHA2A INTERFERON; DACARBAZINE; ONDANSETRON; PARACETAMOL; TROPISETRON;

ADJUVANT THERAPY; ADULT; AGED; AGRANULOCYTOSIS; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL OBSERVATION; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; GERMANY; HUMAN; INFECTION; KAPLAN MEIER METHOD; LEUKOPENIA; LOW DRUG DOSE; LUNG TOXICITY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MONOTHERAPY; MULTICENTER STUDY; NAUSEA AND VOMITING; OVERALL SURVIVAL; PAIN; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN TOXICITY; SURVIVAL RATE; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DACARBAZINE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INTERFERON ALFA-2A; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 44849131339     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn001     Document Type: Article

References (35)

1. Bevona C, Sober AJ. Melanoma incidence trends. Dermatol Clin 2002; 20(4): 589-595.
2. Howe HL, Wingo PA, Thun MJ et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001; 93(11): 824-842.
3. Eigentler TK, Caroli U, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma. A systematic review of 41 randomised clinical trials. Lancet Oncol 2003; 4: 749-753.
4. White RR, Stanley WE, Johnson JL et al. Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis. Ann Surg 2002; 235(6): 879-887.
5. Hersey P. Adjuvant therapy for high-risk primary and resected metastatic melanoma. Intern Med J 2003; 33(1-2): 33-43.
6. Molife R, Hancock BW. Adjuvant therapy of malignant melanoma. Crit Rev Oncol Hematol 2002; 44(1): 81-102.
7. Grob JJ, Dreno B, de la Salmoniere P et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998; 351(9120): 1905-1910.
8. Pehamberger H, Soyer HP, Steiner A et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998; 16(4): 1425-1429.
9. Cameron DA, Cornbleet MC, MacKie RM et al. Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer 2001; 84(9): 1146-1149.
10. Cascinelli N, Belli F, MacKie RM et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomised trial. Lancet 2001; 358(9285): 866-869.
11. Creagan ET, Dalton RJ, Ahmann DL et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alta-2a in selected patients with malignant melanoma. J Clin Oncol 1995; 13(11): 2776-2783.
12. Hancock BW, Wheatley K, Harris S et al. Adjuvant interferon in high-risk melanoma: The AIM HIGH Study - United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Onool 2004; 22(1): 53-61.
13. Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14(1): 7-17.
14. Kirkwood JM, Ibrahim JG, Sondak VK et al. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/ S9111/C9190. J Clin Oncol 2000; 18(12): 2444-2458.
15. Wheatley K, Ives N, Hancock B et al. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003; 29(4): 241-252.
16. Agarwala SS, Neuberg D, Park Y, Kirkwood JM. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): A trial of the Eastern Oncology Group. Cancer 2004; 100(8): 1692-1698.
17. Balch CM, Murray D, Presant C, Bartolucci AA. Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma. Surgery 1984; 95(4): 454-459.
18. Veronesi U, Adamus J, Aubert C et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982; 307(15): 913-916.
19. Falkson CI, Ibrahim J, Kirkwood JM et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 1998; 16(5): 1743-1751.
20. Garbe C. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res 1993; 3(4): 291-299.
21. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: A systematic review of randomized controlled trials. J Clin Oncol 2002; 20(7): 1818-1825.
22. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85(5): 365-376.
23. Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: Good practice and pitfalls. Lancet 2002; 359(9318): 1686-1689.
24. Moher D, Schulz KF, Altman DG. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357(9263): 1191-1194.
25. Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: A meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001; 11(1): 78-81.
26. Bruckner HW, Mokyr MB, Mitchell MS. Effect of imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno) on immunity in patients with malignant melanoma. Cancer Res 1974; 34(l): 181-183.
27. Mitchell MS, Mokyr MB, Davis JM. Effect of chemotherapy and immunotherapy on tumor-specific immunity in melanoma. J Clin Invest 1977; 59(6): 1017-1026.
28. Lev DC, Onn A, Melinkova VO et al. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo J Clin Oncol 2004; 22(11): 2092-2100.
29. Mitchell MS. Chemotherapy for melanoma: The resultant of conflicting vectors. J Clin Oncol 2004; 22(11): 2043-2045.
30. Balch CM, Buzaid AC, Atkins MB et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000; 88(6): 1484-1491.
31. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19(16): 3635-3648.
32. Balch CM, Soong SJ, Gershenwald JE et al. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19(16): 3622-3634.
33. Stadler A, Luger T, Bieber T et al. Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial. Acta Oncol 2006; 45(4): 389-399.
34. Wheatley K, Ives N, Hancock B, Gore M. Interferon as adjuvant treatment for melanoma. Lancet 2002; 360(9336): 878.
35. Eggermont AM, Suciu S, MacKie R et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): Randomised controlled trial. Lancet 2005; 366(9492): 1189-1196.